Media stories about Chemed (NYSE:CHE) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemed earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.4295275051849 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of equities research analysts recently issued reports on CHE shares. ValuEngine lowered Chemed from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Oppenheimer raised their price objective on Chemed from $270.00 to $275.00 and gave the stock an “outperform” rating in a report on Friday, February 16th. Finally, Royal Bank of Canada restated a “hold” rating and set a $258.00 price objective on shares of Chemed in a report on Friday, February 16th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $261.33.
Chemed (NYSE:CHE) opened at $280.40 on Wednesday. The company has a market capitalization of $4,522.08, a price-to-earnings ratio of 48.26 and a beta of 1.10. Chemed has a fifty-two week low of $178.44 and a fifty-two week high of $284.71. The company has a current ratio of 0.91, a quick ratio of 0.88 and a debt-to-equity ratio of 0.17.
Chemed declared that its board has approved a stock repurchase program on Tuesday, March 6th that permits the company to buyback $150.00 million in outstanding shares. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its stock is undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 19th. Shareholders of record on Monday, February 26th will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, February 23rd. This represents a $1.12 annualized dividend and a yield of 0.40%. Chemed’s payout ratio is currently 19.28%.
In other news, insider Kevin J. Mcnamara sold 6,000 shares of Chemed stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $258.00, for a total value of $1,548,000.00. Following the transaction, the insider now directly owns 140,049 shares in the company, valued at approximately $36,132,642. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Naomi C. Dallob sold 1,050 shares of Chemed stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $257.00, for a total value of $269,850.00. Following the completion of the transaction, the vice president now owns 6,649 shares in the company, valued at $1,708,793. The disclosure for this sale can be found here. Company insiders own 4.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/03/21/chemed-che-receiving-somewhat-positive-media-coverage-study-finds/2027068.html.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.